Cardinal Health (CAH)
(Delayed Data from NYSE)
$112.55 USD
+0.57 (0.51%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $112.56 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$112.55 USD
+0.57 (0.51%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $112.56 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
Zacks News
DexCom (DXCM) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
DexCom's (DXCM) G6 censors and lucrative collaborations are likely to drive Q1 results.
BioTelemetry (BEAT) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Products like MCT and Ware Holter are likely to aid BioTelemetry (BEAT) in Q1.
Cerner (CERN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to aid Cerner (CERN) in Q1. However, expected decline in bookings is likely to be a dampener.
Can Diagnostic Revenues Fuel PerkinElmer's (PKI) Q1 Earnings?
by Zacks Equity Research
Strength in PerkinElmer's (PKI) core Diagnostics business is expected to drive Q1 results amid foreign exchange woes.
Thermo Fisher (TMO) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Strong analytical instruments business, product portfolio expansion and prudent growth strategy are likely to support Thermo Fisher (TMO) in Q1. However, forex might act as a dampener.
What's in Store for Align Technology (ALGN) in Q1 Earnings?
by Zacks Equity Research
Higher Invisalign case volume, solid show by Clear Aligner segment and anticipated sturdy growth at Scanner and Service business are likely to support Align Technology (ALGN) in Q1. However, operating expenses are likely to act as dampeners.
Varian Medical (VAR) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Varian Medical (VAR) expects to gain significantly from APAC and EMEA regions in fiscal Q2.
What's in Store for Edwards Lifesciences' (EW) Q1 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) expects to gain from core Critical Care product group in Q1.
UnitedHealth (UNH) Q1 Earnings Beat Estimates, Guides Up
by Zacks Equity Research
UnitedHealth (UNH) Q1 earnings beat on higher revenues and membership.
Cardinal Health (CAH) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Cardinal Health (CAH) closed at $46.79 in the latest trading session, marking a +0.88% move from the prior day.
What's in the Store for UnitedHealth (UNH) Earnings in Q1?
by Zacks Equity Research
UnitedHealth (UNH) should gain from higher revenues, membership partly offset by rise in expenses.
Top Ranked Income Stocks to Buy for April 4th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, April 4th
Will Cardinal (CAH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Can Retail Pharmacy USA Lift Walgreens' (WBA) Q2 Earnings?
by Zacks Equity Research
Widening pharmacy network, healthy prescription volumes along with contributions from Rite Aid are expected to contribute to Walgreens Boots' (WBA) top line in the fiscal second quarter.
CAH or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CAH vs. ALGN: Which Stock Is the Better Value Option?
Is Cardinal Health (CAH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CAH) Outperforming Other Medical Stocks This Year?
Top Ranked Income Stocks to Buy for March 19th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, March 19th
Is Cardinal Health (CAH) a Solid Pick for Value Investors?
by Zacks Equity Research
Let's see if Cardinal Health (CAH) stock is a good choice for value-oriented investors right now from multiple angles.
CAH vs. ALGN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CAH vs. ALGN: Which Stock Is the Better Value Option?
Why Is Cardinal (CAH) Down 12.1% Since Last Earnings Report?
by Zacks Equity Research
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Cardinal Health (CAH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Top Ranked Income Stocks to Buy for March 6th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, March 6th
Here's Why You Should Hold Becton, Dickinson Stock for Now
by Zacks Equity Research
Becton, Dickinson's (BDX) MAX enteric viral panel receives FDA clearance.
Cardinal Health Strong on Pharmaceutical, Competition Rife
by Zacks Equity Research
Cardinal Health (CAH) is on track to deliver targeted annualized cost savings of $100 million in fiscal 2019.